Invion Reports 79% Disease Control in Phase 1 Skin Cancer Trial
Invion closed Phase 1 recruitment in non-melanoma skin cancer, reporting 79% disease control across 14 patients — an early signal now awaiting full data readout.
Topic
Clinical Trial
Topic
Clinical Trial
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech reports over 80% lesion reduction in a rare skin cancer trial, though phase, enrollment and durability data remai…
Nemolizumab Phase II Shows Lasting Relief in Children's Atopic Dermatitis
Phase II data presented at PeDRA 2026 show nemolizumab delivered long-term symptom relief in children aged 2 to 11 with moderate-…
New Trial to Test MRD-Guided Escalation in Advanced Melanoma
A newly announced trial will evaluate whether measurable residual disease testing can trigger earlier treatment escalation in adv…
First Patient Treated in Trial Targeting Immunotherapy Resistance
The Institute of Cancer Research has treated the first patient in a new clinical trial targeting immunotherapy resistance in lung…
MRD-Guided Melanoma Trial Enrolls First Patients With Signatera
First patients enrolled in NCT07504796: Signatera-positive melanoma patients randomized at week six to ipilimumab escalation or c…
IDO1 Inhibitor Fails to Amplify T-Cell Response to Melanoma Vaccine
A clinical trial reports that combining an IDO1 inhibitor with a melanoma vaccine did not increase tumor-fighting T cells, underm…
Upadacitinib Sustains Repigmentation at Week 76 in Non-Segmental Vitiligo
Long-term extension data show repigmentation maintained through 76 weeks in non-segmental vitiligo patients receiving oral upadac…
Natera Launches Randomized Signatera-Guided Interventional Melanoma Study
Natera will run a randomized interventional melanoma study using its tumor-informed Signatera ctDNA assay to guide treatment, shi…
Zasocitinib Beats Deucravacitinib Head-to-Head in Phase 3 Psoriasis
In the Phase 3 LATITUDE Atlas head-to-head trial, zasocitinib achieved PASI-100 in 36.5% of patients at Week 16 versus 13.9% for…